Document Detail


Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
MedLine Citation:
PMID:  21417950     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases. Many autoimmune diseases occur in women of child-bearing age who may become pregnant while on therapy, which raises concerns regarding the teratogenicity of HCQ and its effect on the outcome of the pregnancy. There is a lack of data regarding the safety of HCQ during pregnancy.
AREAS COVERED: In this review, the authors attempt to identify relevant publications by searching MEDLINE, Cochrane database, Ovid-Currents Clinical Medicine, Ovid-Embase:Drugs and Pharmacology, EBSCO, Web of Science and SCOPUS using the search terms HCQ and/or pregnancy. A basis for the mechanism of action of HCQ is provided.
EXPERT OPINION: HCQ has been shown by numerous studies over the past 15 years to be efficacious in the treatment of autoimmune diseases, including systemic lupus erythematosus, discoid lupus erythematosus and rheumatoid arthritis. HCQ does not appear to be associated with any increased risk of congenital defects, spontaneous abortions, fetal death, prematurity or decreased numbers of live births in patients with autoimmune diseases. Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy.
Authors:
Crispin Abarientos; Kirk Sperber; Deborah L Shapiro; Wilbert S Aronow; Chun Peng Chao; Julia Y Ash
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-22
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  10     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-18     Completed Date:  2012-02-15     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  705-14     Citation Subset:  IM    
Affiliation:
New York Medical College, Division of Allergy, Immunology and Rheumatology, Munger Pavilion, Valhalla, NY 10595, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antirheumatic Agents / adverse effects,  therapeutic use
Arthritis, Rheumatoid / drug therapy*
Clinical Trials as Topic
Female
Humans
Hydroxychloroquine / adverse effects*,  therapeutic use*
Lupus Erythematosus, Systemic / drug therapy*
Pregnancy
Pregnancy Complications / chemically induced*,  drug therapy*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 118-42-3/Hydroxychloroquine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hyponatremia, Hypochloremia, and Hypoalbuminemia Predict an Increased Risk of Mortality during the F...
Next Document:  Aclidinium bromide in experimental asthma.